A Form 4 filed on August 20, 2026, with the SEC reports that Brian JG Pereira, a director of ProKidney Corp., sold all of his directly and indirectly held Class A Common Stock across three consecutive trading days ending August 20, 2026.

Key Highlights

  • Director identity: Brian JG Pereira, listed as a director of ProKidney Corp. (NASDAQ:PROK), is the reporting person.
  • August 18 sales: 229,338 shares sold indirectly and 27,826 shares sold directly at a weighted average price of $1.3712, with individual transaction prices ranging from $1.345 to $1.40.
  • August 19 sales: 222,949 shares sold indirectly and 27,051 shares sold directly at a weighted average price of $1.4407, with prices ranging from $1.38 to $1.50.
  • August 20 sales: 222,948 shares sold indirectly and 27,052 shares sold directly at a weighted average price of $1.4199, with prices ranging from $1.38 to $1.47.
  • Resulting ownership: Following all reported transactions, Pereira holds 0 shares both directly and indirectly through the Brian J. G. Pereira 2012 Irrevocable Trust.
  • All transaction codes: All six reported transactions carry code "S," indicating open-market sales.

Brian Pereira Disposes of Full ProKidney Stake Across Three Trading Sessions

According to the filing, Brian JG Pereira, a director at ProKidney Corp., executed a series of Class A Common Stock sales on August 18, 19, and 20, 2026. The shares were held in two forms: directly in his own name and indirectly through the Brian J. G. Pereira 2012 Irrevocable Trust. All transactions carry transaction code "S," denoting sales on the open market.

On August 18, the filing reports sales of 229,338 shares held indirectly and 27,826 shares held directly, both at a weighted average price of $1.3712. The footnotes disclose that these were sold in multiple transactions at prices ranging from $1.345 to $1.40, inclusive. Following these sales, the trust held 445,897 shares and the direct account held 54,103 shares, according to the filing.

On August 19, an additional 222,949 indirect shares and 27,051 direct shares were sold at a weighted average price of $1.4407, with individual prices ranging from $1.38 to $1.50, inclusive. On August 20, the remaining 222,948 indirect shares and 27,052 direct shares were sold at a weighted average price of $1.4199, with prices ranging from $1.38 to $1.47, inclusive. After all reported transactions, the beneficial ownership in both the direct and indirect accounts stands at 0 shares, as disclosed in the filing. The filing was signed by Todd Girolamo as attorney in fact on August 20, 2026.

What Was Disclosed

The Form 4 discloses that ProKidney Corp. director Brian JG Pereira sold all of his directly and indirectly held Class A Common Stock in six open-market transactions over August 18-20, 2026, leaving him with zero shares beneficially owned in either capacity.